Kalvista Pharmaceuticals (KALV) Stock Price Up 18.6%

Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) rose 18.6% on Thursday . The company traded as high as $34.92 and last traded at $31.10. Approximately 514,390 shares changed hands during trading, an increase of 529% from the average daily volume of 81,766 shares. The stock had previously closed at $26.23.

KALV has been the topic of a number of research analyst reports. TheStreet raised shares of Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, December 20th. BidaskClub upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, January 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $32.00 price objective on shares of Kalvista Pharmaceuticals in a report on Friday, December 14th. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 price objective on the stock in a report on Saturday, March 2nd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $27.00.

The firm has a market capitalization of $411.35 million, a price-to-earnings ratio of -20.33 and a beta of 2.45.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.24. Kalvista Pharmaceuticals had a negative net margin of 84.47% and a negative return on equity of 29.46%. The company had revenue of $5.59 million for the quarter, compared to analyst estimates of $3.70 million. Equities research analysts expect that Kalvista Pharmaceuticals Inc will post -1.65 earnings per share for the current year.

In related news, major shareholder Svlsf Iv, Llc sold 43,378 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $22.91, for a total value of $993,789.98. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Life Sciences Fund Iv (Gp) Sv sold 214,198 shares of the company’s stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $20.55, for a total transaction of $4,401,768.90. The disclosure for this sale can be found here. Insiders sold a total of 314,718 shares of company stock worth $6,509,410 in the last 90 days. 38.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Flinton Capital Management LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the 4th quarter worth about $26,000. Ramsey Quantitative Systems bought a new position in shares of Kalvista Pharmaceuticals during the 4th quarter valued at approximately $35,000. Bank of Montreal Can bought a new position in shares of Kalvista Pharmaceuticals during the 4th quarter valued at approximately $90,000. Virtu Financial LLC bought a new position in shares of Kalvista Pharmaceuticals during the 3rd quarter valued at approximately $216,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Kalvista Pharmaceuticals during the 3rd quarter valued at approximately $274,000. Institutional investors own 77.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Kalvista Pharmaceuticals (KALV) Stock Price Up 18.6%” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2019/03/14/kalvista-pharmaceuticals-kalv-stock-price-up-18-6.html.

Kalvista Pharmaceuticals Company Profile (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Relative Strength Index

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit